AEON · AEON Biopharma, Inc.
$0.31
+0.02 (+6.91%)
At close · Aug 28
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of these conditions, management has concluded that substantial doubt about our ability to continue as a going concern exists as conditions and events, considered in the aggregate, indicate that it is probable that we will be unable to meet our obligations as they become due within one year after the date that the financial statements included in this Report are issued.”View the 10-Q filed Aug 12, 2026
Market Cap
$15.67M
Shares
49.88M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$39.22M
-193.4%
FY2025
Diluted EPS
-$3.95
-105.4%
FY2025
Operating Cash Flow
-$17.31M
+14.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| $7.18M | $4.09M | $14.18M | $34.75M | — | |
| $12.72M | $12.21M | $13.64M | $13.68M | — | |
| $78K | $78K | $97K | $68K | — | |
| $19.86M | $12.8M | -$72.99M | $48.43M | — | |
| -$19.86M | -$12.8M | $72.99M | -$48.43M | -$1.94M | |
| $5.34M | — | — | $3.71M | $79.69K | |
| -$34.77M | -$26.42M | -$30.98M | -$4.13M | $10.14M | |
| -$54.62M | -$39.22M | $42.01M | -$52.56M | $8.2M | |
| — | $0 | $0 | $0 | — | |
| -$54.62M | -$39.22M | $42.01M | -$52.56M | $8.2M | |
| — | -$39.22M | $42.01M | -$52.56M | — | |
| USD/shares | -$5.94 | -$3.95 | $77.74 | -$27.36 | — |
| USD/shares | -$5.94 | -$3.95 | $72.93 | -$27.36 | — |
| shares | — | 9.92M | 540.36K | 1.93M | — |
| shares | — | 9.92M | 575.95K | 1.93M | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.62×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.89×
Peer medians compare against the 228 similar-size Biotechnology companies (of 524 listed).
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Single Reportable Segment | -$12,803,000 | $72,985,000 |
Key facts
CIK
1837607
CUSIP
00791X209
13F (30d)
18 filings
18 filers
Visit website
Investor relations